Corbus Pharmaceuticals (CRBP) has received reaffirmed Buy ratings from both H.C. Wainwright and Oppenheimer despite a recent stock decline triggered by disappointing data from Novo Nordisk’s obesity drug. Analysts remain optimistic about Corbus’ diverse pipeline, highlighting the potential of its CRB-913 and CRB-701.